본문으로 건너뛰기
← 뒤로

Anaplastic Lymphoma Kinase (ALK)-Positive Large B-cell Lymphoma in Children: A Case Report and Review of Literature.

증례보고 1/5 보강
Cureus 📖 저널 OA 99.9% 2021: 42/43 OA 2022: 79/79 OA 2023: 181/181 OA 2024: 284/284 OA 2025: 774/774 OA 2026: 506/506 OA 2021~2026 2026 Vol.18(2) p. e102952 OA
Retraction 확인
출처

Dananjaya R, Harahap AS, Sari TT, Ilmana G, Chozie NA, Ardhiawan AV, Ham MF

📝 환자 설명용 한 줄

Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK⁺-LBCL) is an aggressive and rare B-cell lymphoma caused by the ALK gene mutation.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Dananjaya R, Harahap AS, et al. (2026). Anaplastic Lymphoma Kinase (ALK)-Positive Large B-cell Lymphoma in Children: A Case Report and Review of Literature.. Cureus, 18(2), e102952. https://doi.org/10.7759/cureus.102952
MLA Dananjaya R, et al.. "Anaplastic Lymphoma Kinase (ALK)-Positive Large B-cell Lymphoma in Children: A Case Report and Review of Literature.." Cureus, vol. 18, no. 2, 2026, pp. e102952.
PMID 41798535 ↗

Abstract

Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK⁺-LBCL) is an aggressive and rare B-cell lymphoma caused by the ALK gene mutation. It is exceptionally rare in children and typically presents at advanced stages. Due to morphological mimicry of other hematologic malignancies and conditions, diagnosis remains challenging. Moreover, prognosis is poor as there is a lack of standard therapy. We report the case of a 13-year-old Indonesian male who presented with abdominal pain, initially presumed to be appendicitis. Multiple abdominal masses were subsequently identified following surgery. Histopathological examination revealed diffuse sheets of large round cells with plasmablastic morphology and numerous mitotic figures. Immunohistochemical analysis demonstrated positive ALK expression with a granular cytoplasmic pattern, weak CD45 expression, strong positivity for CD38, MUM1, and EMA, a Ki-67 proliferation index of approximately 70%, and negativity for B- and T-cell markers. Staging confirmed ALK⁺-LBCL, stage IV, according to the Murphy and St. Jude Children's Research Hospital staging system, with both nodal and extranodal involvement. The patient was treated with CHOP chemotherapy, with alectinib added from the second cycle. A partial response was achieved after four cycles and was sustained for more than one year. Notably, neuron-specific enolase levels increased in parallel with disease progression. This case highlights diagnostic challenges related to an unusual clinical presentation and pathological overlap with other hematologic diseases.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기